GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ALKS-8700 | ALKS8700 | BIIB098 | Vumerity®
                                 
                                                         
                            
                            
                            
                                 
                                
                                diroximel fumarate is an approved drug (FDA (2019), EMA (2021)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Diroximel fumarate is a novel oral fumarate prodrug. It is rapidly converted to monomethyl fumarate, which is the same active metabolite of dimethyl fumarate.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| FDA approval of diroximel fumarate (October 2019) allows it use as a treatment for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Phase 3 study results indicate that diroximel fumarate has improved patient-reported gastrointestinal tolerability compared to dimethyl fumarate (Tecfidera®) [1]. |